GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL
Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy
FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug
Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden
ASCO Recommends Discussing Pharmacological Prevention
Elderly and Younger Patients Have Similar Outcomes Following Radioembolization
Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness
Statistical Models Determine Stem-Cell Transplant Effectiveness
Phase II Elotuzumab Study Demonstrates 33 Months PFS
Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study
Biomarker Test Outperforms PSA and Gleason Score in Study
NCI CTEP Approved Trials For the Month of July
FDA Approves Implant For Breast Reconstruction
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- What NHS-Galleri taught us—and what it didn’t
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
